Cognisharp

Lowers blood glucose and offers cardiometabolic protection

Cognisharp | Arcturus Pharma

Cognisharp (L Carnosine), a histidine-containing dipeptide (HCD), is synthesised by bonding of the amino acids β-alanine and L-histidine, a reaction catalysed by carnosine synthase. L carnosine is not naturally found in humans.

Carnosine supplementation was found to decrease HbA1C levels. A 12 week study has demonstrated that two-hour glucose and insulin were both lower after carnosine supplementation1*.

Carnosine acts as an anti-glycating agent, reducing the rate of formation of advanced glycation end-products. AGEs can be a factor in the development or worsening of many degenerative diseases, such as diabetes, atherosclerosis, chronic kidney failure, and Alzheimer’s disease. Many studies have demonstrated carnosine’s role in metabolic and cardiovascular disorders.

In addition, Carnosine has promising inhibitory interactions with host ACE2 and nCoV spike protein and hence could offer a potential mitigating effect against the current COVID-19 pandemic too2*.

Thus, Cognisharp (L Carnosine), a safe and natural substance with proven anti-glycaemic effect reduces risk due to cardiometabolic complications and offers protective action against viral infection.

Pack Size: 60 Tablets (1 Month Course)
Rs. 2800.00
Rs. 2592.00

Add to Cart

Pack Size: 180 Tablets (3 Month Course)
Rs. 8640.00
Rs. 4800.00

Add to Cart

fssai-300px

Pack Size: 60 Tablets (1 Month Course)
Rs. 2800.00
Rs. 2592.00

Add to Cart

Pack Size: 180 Tablets (3 Month Course)
Rs. 8640.00
Rs. 4800.00

Add to Cart

fssai-300px

Cognisharp (L Carnosine), a histidine-containing dipeptide (HCD), is synthesised by bonding of the amino acids β-alanine and L-histidine, a reaction catalysed by carnosine synthase. L carnosine is not naturally found in humans.

Carnosine supplementation was found to decrease HbA1C levels. A 12 week study has demonstrated that two-hour glucose and insulin were both lower after carnosine supplementation1*.

Carnosine acts as an anti-glycating agent, reducing the rate of formation of advanced glycation end-products. AGEs can be a factor in the development or worsening of many degenerative diseases, such as diabetes, atherosclerosis, chronic kidney failure, and Alzheimer’s disease. Many studies have demonstrated carnosine’s role in metabolic and cardiovascular disorders.

In addition, Carnosine has promising inhibitory interactions with host ACE2 and nCoV spike protein and hence could offer a potential mitigating effect against the current COVID-19 pandemic too2*.

Thus, Cognisharp (L Carnosine), a safe and natural substance with proven anti-glycaemic effect reduces risk due to cardiometabolic complications and offers protective action against viral infection.

Who benefits from Cognisharp

Given the relationship to diabetes in the majority of incidence of mortality with n-covid 19, use of Cognisharp, L Carnosine, as an adjuvant treatment for people with pre-existing diabetes, including borderline, may benefit.

Cognisharp, L Carnosine, also will offer overall benefit to most elderly people even if they are asymptomatic but is at risk of increased blood glucose levels.

Cognisharp composition
Each tablet contains 200 mg of L carnosine

Recommended dosage & directions

Usual dosage is 2 tablets daily. May be increased as needed.

Although some early benefits may be experienced, it is recommended that Cognisharp should be taken daily for at least 3 months, to get the full benefits evidenced in clinical studies.

Caution: While there are no known serious drug interactions, caution should be exercised in the concomitant use with antihypertensives reporting lowered BP.

Frequent monitoring of BP and blood glucose is therefore recommended as a matter of general precaution to avoid any sudden and unmonitored drops.

It is recommended that you talk to your healthcare professional before taking any supplements and also if you experience any difficulty or have any questions about using Cognisharp

References
1. Barbora de Courten et al. Obesity (Silver Spring). 2016 May;24(5):1027-34,
2. Loai M. Saadah et al., Molecules 2020, 25, 5605